D-penicillamine in patients with rheumatoid arthritis. Serum levels, pharmacokinetic aspects, and correlation with clinical course and side effects.
After administration of D-penicillamine to patients with rheumatoid arthritis, measurements of serum level and urinary excretion showed half-life times of 1.6 hours in the rapid phase and 4-6 days in the slow phase. The latter evidence suggests that tissue pooling occurs. With a dosage of 750 mg/day, basic serum levels of 100 microM are gradually reached. Serum D-penicillamine levels were shown to be the same for patients who responded well to treatment, those who did not respond, and for patients who had adverse side effects as well as those who had none. Intestinal resorption decreased when D-penicillamine was taken close to meals and was greatly reduced by iron preparations.
D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism; D003545:Cysteine / Q000097:blood; D004334:Drug Administration Schedule; D006801:Humans; D007408:Intestinal Absorption; D007700:Kinetics; D010396:Penicillamine / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use* / Q000652:urine; D013997:Time Factors
D010396:Penicillamine; D003545:Cysteine